ES2662801T3 - Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas - Google Patents

Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas Download PDF

Info

Publication number
ES2662801T3
ES2662801T3 ES13735511.1T ES13735511T ES2662801T3 ES 2662801 T3 ES2662801 T3 ES 2662801T3 ES 13735511 T ES13735511 T ES 13735511T ES 2662801 T3 ES2662801 T3 ES 2662801T3
Authority
ES
Spain
Prior art keywords
suis
strain
seq
nos
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13735511.1T
Other languages
English (en)
Inventor
Russell F. Bey
Paulraj Kirubakaran LAWRENCE
Randy R. SIMONSON
Kamesh Reddy SIRIGIREDDY
Danielle A. McKEOWN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Application granted granted Critical
Publication of ES2662801T3 publication Critical patent/ES2662801T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cepa de Streptococcus suis (S. suis) atenuada capaz de proporcionar una respuesta inmunitaria segura y eficaz en animales porcinos contra S. suis o enfermedades causadas por S. suis, en la que la cepa tiene sustituciones de aminoácidos en los genes de virulencia rpsL-S12 (una proteína de la subunidad ribosomal 30S), una proteína de membrana de unión a ATP transportadora ABC (ABC-ATPBMP) y un regulador de la transcripción marR con respecto a la cepa de S. suis parental virulenta, en la que dicha cepa parental comprende ácidos nucleicos que codifican proteínas de tipo natural que tienen secuencias de péptidos, tal como se establecen en las SEQ ID NOs: 2, 6 y 10, y en la que la cepa atenuada tiene secuencias de ácido nucleico que codifican la secuencia de aminoácidos, tal como se establecen en las SEQ ID NOs: 4, 8 y 12.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
ES13735511.1T 2012-06-27 2013-06-24 Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas Active ES2662801T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664935P 2012-06-27 2012-06-27
US201261664935P 2012-06-27
PCT/US2013/047282 WO2014004361A1 (en) 2012-06-27 2013-06-24 Attenuated streptococcus suis vaccines and methods of making and use thereof

Publications (1)

Publication Number Publication Date
ES2662801T3 true ES2662801T3 (es) 2018-04-09

Family

ID=48782624

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13735511.1T Active ES2662801T3 (es) 2012-06-27 2013-06-24 Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas

Country Status (18)

Country Link
US (1) US9289484B2 (es)
EP (1) EP2866828B1 (es)
JP (1) JP6262728B2 (es)
KR (1) KR102126096B1 (es)
CN (1) CN104780935B (es)
AR (1) AR091582A1 (es)
AU (2) AU2013280718B2 (es)
BR (1) BR112014032636A2 (es)
CA (1) CA2877817A1 (es)
DK (1) DK2866828T3 (es)
EA (1) EA036764B1 (es)
ES (1) ES2662801T3 (es)
MX (1) MX365879B (es)
MY (1) MY173796A (es)
NZ (1) NZ703701A (es)
PH (1) PH12014502855B1 (es)
PL (1) PL2866828T3 (es)
WO (1) WO2014004361A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132183B2 (en) * 2007-03-09 2015-09-15 Newport Laboratories Modified live (JMSO strain) Haemophilus parasuis vaccine
US10280199B2 (en) 2014-02-07 2019-05-07 Phibro Animal Health Corporation Coronavirus proteins and antigens
ES2942260T3 (es) 2014-09-14 2023-05-31 Tel Hashomer Medical Res Infrastructure & Services Ltd Ligandos sintéticos de receptores de somatostatina
CN105348373B (zh) * 2015-11-24 2019-01-11 武汉天种畜牧股份有限公司 猪链球菌血清3型的粘附性抗原ssust3_1962及其制备方法和应用
US10279031B2 (en) 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
EP3454893A4 (en) * 2016-05-11 2020-01-01 Phibro Animal Health Corporation A composition comprising antigens and a mucosal adjuvant and a method for using
CA3054765A1 (en) 2017-03-15 2018-09-20 London School Of Hygiene And Tropical Medicine Whole cell vaccines
JP2020529408A (ja) * 2017-08-03 2020-10-08 インターベット インターナショナル ベー． フェー． ストレプトコッカス・スイスに対する防御のためのワクチン
CN111328289A (zh) * 2017-08-31 2020-06-23 勃林格殷格翰动物保健美国公司 预防生殖、育龄和生长猪的疾病的猪链球菌疫苗及其制备和使用方法
CN111447945A (zh) * 2017-12-15 2020-07-24 英特维特国际股份有限公司 用于保护以抗猪链球菌的疫苗
CN110327460A (zh) * 2019-06-05 2019-10-15 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 猪链球菌病-副猪嗜血杆菌病二联亚单位疫苗及制备方法
CN112694988B (zh) * 2020-12-15 2022-12-06 武汉市农业科学院 一种鸡源猪链球菌弱毒株及其应用
CN115161333B (zh) * 2022-06-23 2023-08-25 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种猪链球菌的反向筛选标记、含有该反向筛选标记的猪链球菌及其应用
CN120399980B (zh) * 2025-06-30 2025-11-21 杭州依思康医药科技有限公司 猪链球菌2型荚膜多糖高产菌株及应用
CN120843391A (zh) * 2025-07-02 2025-10-28 华中农业大学 一种无乳链球菌弱毒株、疫苗及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3529056A (en) * 1968-05-07 1970-09-15 American Home Prod Method of producing jowl abscess vaccine
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6455323B1 (en) * 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6379676B2 (en) * 1999-03-10 2002-04-30 Anitox Corporation Enhancing immune response in animals
KR20040091698A (ko) * 2002-03-08 2004-10-28 쉐링-플라우 리미티드. 신규한 플로르페니콜형 항생제
JP4500615B2 (ja) * 2004-07-14 2010-07-14 日生研株式会社 エリシペロトリックス属のその他の菌種である血清型１８由来の豚丹毒菌感染防御活性を有する新規ポリペプチドとその遺伝子および製法
WO2007116322A2 (en) * 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
BRPI1008561A2 (pt) * 2009-02-20 2018-07-24 Australian Poultry Crc Pty Ltd vacinas vivas atenuadas
KR101209964B1 (ko) * 2010-10-15 2012-12-07 주식회사 동방 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법

Also Published As

Publication number Publication date
EA201500054A1 (ru) 2015-06-30
WO2014004361A1 (en) 2014-01-03
AR091582A1 (es) 2015-02-11
AU2016222520A1 (en) 2016-09-22
US9289484B2 (en) 2016-03-22
MY173796A (en) 2020-02-24
AU2013280718B2 (en) 2016-06-09
MX2015000045A (es) 2015-03-05
CN104780935A (zh) 2015-07-15
PH12014502855A1 (en) 2015-02-09
BR112014032636A2 (pt) 2017-08-29
KR20150033692A (ko) 2015-04-01
PH12014502855B1 (en) 2015-02-09
CA2877817A1 (en) 2014-01-03
US20140004144A1 (en) 2014-01-02
MX365879B (es) 2019-06-18
EP2866828A1 (en) 2015-05-06
HK1203834A1 (en) 2015-11-06
EP2866828B1 (en) 2017-12-13
AU2013280718A1 (en) 2015-02-12
KR102126096B1 (ko) 2020-06-23
JP2015522282A (ja) 2015-08-06
PL2866828T3 (pl) 2018-04-30
EA036764B1 (ru) 2020-12-17
JP6262728B2 (ja) 2018-01-17
DK2866828T3 (en) 2018-01-15
CN104780935B (zh) 2018-01-02
AU2016222520B2 (en) 2018-03-22
NZ703701A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
ES2662801T3 (es) Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas
IL263249B (en) A polypeptide isolated from btv virus which causes an immune response in an animal and a polypeptide containing a DNA segment that codes for an epitope or an antigenic determinant of the btv polypeptide
JP2011136997A5 (es)
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
WO2011163628A3 (en) Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof
PH12015500308B1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
PH12014502534B1 (en) Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
UY34860A (es) Sistema de expresión en cho.
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
EA201892795A1 (ru) Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
CL2012002900A1 (es) Secuencias de acido nucleico procedente de un virus causante del sindrome de miocardiopatia (cms) en peces; vector; celula huesped; vacuna de adn; proteina recombinante codificada; vacuna recombinante; inmunoensayo para la deteccion de dicho virus; kit de diagnostico; y uso de las mismas.
EP4353256A3 (en) Induction of cross-reactive cellular response against rhinovirus antigens
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
HRP20161623T1 (hr) Rekombinantna mikobakterija kao cjepivo
BR112015027611A2 (pt) Molécula de ácido nucleico isolada; célula hospedeira; vetor; proteína ou polipeptídeo isolado; imunorreagente específico de vírus da febre do vale do rift (rvfv); uso de uma composição; uso de uma composição para o diagnóstico de febre do vale do rift (rvf) em um indivíduo; e kit
WO2012178078A3 (en) Use of yscf, truncated yscf and yscf homologs as adjuvants
UY36802A (es) Vacuna contra la garrapata bovina conteniendo dos proteinas o peptidos derivados